Syn-Ake: A Literature Course on What the Research Reports

Syn-Ake is a trade name attached to a synthetic peptide cosmetic ingredient that was developed with reference to waglerin, a peptide family identified in the venom of the temple pit viper Tropidolaemus wagleri. A 2017 evolutionary analysis described the molecular origin and evolution of the waglerin peptides used in anti-wrinkle skin cream, making explicit the link between a snake-venom peptide family and a cosmetic ingredient concept (PMID 27864608). This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to health, skin or medication.

This course is organised into six modules. Each module ends with an explicit statement of what the evidence in that module cannot support. Nothing here is instruction, and no module describes a regimen, protocol or application schedule.

Module 1 — What Syn-Ake Is and How It Has Been Studied

Definition and naming

Syn-Ake is a commercial ingredient name, not a compound name assigned by a pharmacopoeia. Cosmetic ingredient nomenclature identifies it as a small synthetic peptide derivative, and secondary sources describe it inconsistently — some call it a dipeptide derivative, others a tripeptide. The verified literature does not adjudicate that description, so this page does not assert a specific peptide length or class beyond "small synthetic peptide." That ambiguity matters, because the biological literature that is usually cited alongside the ingredient concerns waglerin-1, a distinctly different and larger venom peptide characterised in receptor studies (PMID 11724791).

Biological origin of the reference peptide

The waglerin family has been mapped repeatedly in the venom of Tropidolaemus wagleri. A 2016 shotgun-proteomics study characterised and compared Malaysian Tropidolaemus wagleri and Cryptelytrops purpureomaculatus venoms and reported waglerin peptides as a defining component of the T. wagleri proteome (PMID 27763534). A 2017 venomics study of the sexually dimorphic temple pit viper reported a deeply conserved and atypical toxin arsenal in this species (PMID 28240232). A 2023 venom-gland transcriptome assembly examined the origin of waglerin as the species' major toxin (PMID 37756011). Broader work on how venom proteomes arise from body proteins provides the evolutionary framing for that toxin recruitment (PMID 15741511).

Forms described in the literature

The evolutionary review situated waglerin-derived peptide chemistry in topical anti-wrinkle skin cream products (PMID 27864608). The only indexed study naming Syn-Ake itself evaluated the peptide with in silico approaches and in vitro tests rather than in a finished consumer product used by human volunteers (PMID 37349941). Synthetic research-grade peptide material is also distributed under research-use-only labelling; that is a labelling and regulatory fact, not a study finding, and it is discussed in Module 6.

Limits of the evidence in Module 1: the verified papers establish where waglerin comes from and that it inspired a cosmetic ingredient. They do not establish a definitive structural class for the ingredient sold as Syn-Ake, do not compare the ingredient side by side with waglerin-1, and do not describe manufacturing, purity or formulation standards.

Module 2 — Mechanism as Described in the Literature

What was actually characterised: waglerin-1 at the muscle nicotinic receptor

The mechanistic literature belongs to the venom peptide, not the cosmetic ingredient. Researchers identified residues at the α and ε subunit interfaces that mediate the species selectivity of waglerin-1 for nicotinic acetylcholine receptors (PMID 11724791). A companion 2002 study reported that residues in the ε subunit interact to confer waglerin-1 selectivity for the α–ε subunit interface site (PMID 12069578). Because the ε subunit is characteristic of the adult muscle-type receptor, a 2008 overview described peptide toxins of this kind as tools for probing the expression and function of fetal and adult nicotinic receptor subtypes (PMID 18567854).

Why receptor composition is not static

Muscle nicotinic receptor populations can change with physiological state. A 2014 study reported that immobilisation with atrophy induced de novo expression of neuronal nicotinic α7 acetylcholine receptors in muscle that contributed to neurotransmission (PMID 24126263). That finding is relevant context: a peptide whose selectivity depends on a particular subunit interface interacts with a target whose subunit composition is not fixed.

Comparative venom ligands

Waglerin is not the only viper peptide characterised at this receptor. A 2012 study described azemiopsin from Azemiops feae venom as a novel polypeptide ligand of the nicotinic acetylcholine receptor (PMID 22613724). Comparative work of this type is how researchers separate a shared receptor family from claims about any one peptide.

The extrapolation to be careful about

The popular account — that a small synthetic peptide applied to skin reproduces waglerin-1's receptor antagonism at human facial neuromuscular junctions — is an extrapolation, not a demonstrated finding in the verified literature. The receptor-interface work was performed on nicotinic receptors in experimental preparations with waglerin-1 (PMID 11724791, PMID 12069578), while the study naming Syn-Ake used in silico approaches and in vitro tests (PMID 37349941). None of the verified papers reported measurements of a topical cosmetic peptide reaching, binding or blocking neuromuscular junctions in intact human skin.

Limits of the evidence in Module 2: mechanism here is receptor pharmacology for a venom peptide plus computational and cell-level work for the ingredient. There is no verified bridging study connecting the two in human tissue, and no verified study reporting skin penetration depth, dermal concentration or functional effect at a human neuromuscular junction.

Module 3 — Reported Outcomes by Study

The table below summarises what each verified paper examined and what researchers reported at the level of the published title and abstract scope. No effect size, percentage or duration is stated because the verified list does not supply one for the ingredient.

Limits of the evidence in Module 3: only one verified study named the ingredient, and it was computational and in vitro (PMID 37349941). There is no verified randomised, controlled or blinded human trial of Syn-Ake in this evidence set, no verified comparison against another cosmetic ingredient, and no verified long-term follow-up. In silico docking and cell-level assays do not predict clinical outcomes.

Module 4 — Syn-Ake Side Effects: What Studies Report

Across the verified literature, no study reported adverse events in humans exposed to Syn-Ake. The single ingredient-focused paper was an in silico and in vitro investigation rather than a safety or tolerability trial, so it did not generate human adverse-event data (PMID 37349941). The receptor-selectivity studies characterised waglerin-1 interactions with nicotinic acetylcholine receptor subunit interfaces in experimental systems and likewise did not report human tolerability outcomes (PMID 11724791, PMID 12069578).

The relevant safety context in these papers is toxinological rather than cosmetic. Waglerin peptides were characterised as major components of a viper venom proteome (PMID 27763534) and as the dominant toxin of the species in transcriptomic analysis (PMID 37756011), and comparable viper peptides such as azemiopsin were reported to act as ligands at nicotinic acetylcholine receptors (PMID 22613724). Because receptor subunit composition in muscle can change with disuse and atrophy (PMID 24126263), researchers treat the target itself as variable rather than uniform across individuals.

Limits of the evidence in Module 4: absence of reported adverse events in a small set of laboratory papers is not evidence of safety. No verified study reported dermal irritation testing, sensitisation testing, ocular safety, systemic exposure or use in pregnancy, and none reported outcomes from any non-topical route.

Module 5 — Pharmacokinetics Where Data Exist

The verified literature contains no pharmacokinetic dataset for Syn-Ake: no absorption, distribution, metabolism, elimination, half-life, bioavailability or skin-permeation measurements were reported in the ingredient study, which was described as in silico plus in vitro (PMID 37349941). The receptor papers examined binding selectivity at defined subunit interfaces rather than systemic disposition (PMID 12069578).

What does exist is adjacent chemistry. A 2008 solution study reported the binding of Ni²⁺ and Cu²⁺ ions to peptides containing a Cys-His motif (PMID 18827939), an example of how peptide stability and coordination behaviour are studied at the bench. Evolutionary and proteomic work also documents that venom peptides are structurally constrained and conserved (PMID 28240232, PMID 15741511), but structural conservation is not a pharmacokinetic parameter.

Limits of the evidence in Module 5: there is no verified human or animal pharmacokinetic study of Syn-Ake or waglerin-1 in this evidence set. Any figure circulating for penetration, retention or clearance of this ingredient is not supported by the papers listed below.

Module 6 — Regulatory Status, Stated Factually

• Cosmetic use. The evolutionary analysis explicitly described waglerin peptides in the context of anti-wrinkle skin cream, confirming a cosmetic rather than pharmaceutical framing for the ingredient concept (PMID 27864608).
• No approved drug product. There is no FDA-approved drug product whose active ingredient is Syn-Ake or waglerin-1. In the United States, cosmetics other than colour additives are not subject to FDA pre-market approval; a cosmetic ingredient's presence in commerce does not indicate that an agency reviewed efficacy claims.
• Research-use-only material. Synthetic peptide material sold with research-use-only labelling is designated for laboratory investigation and is not labelled for human administration. RUO status is a labelling category, not an indication of safety or effectiveness.
• Compounding. Under the US Federal Food, Drug, and Cosmetic Act, sections 503A and 503B govern compounded preparations, and bulk drug substances used in compounding must generally be the subject of an applicable USP monograph, a component of an FDA-approved drug, or appear on the relevant FDA list. Syn-Ake does not correspond to an approved drug active ingredient.
• Other jurisdictions. Cosmetic ingredient regulation differs by country, including ingredient listing and safety-assessment requirements in the European Union.

This section states regulatory facts for educational context and is not legal advice; regulatory classifications change and vary by jurisdiction.

Limits of the evidence in Module 6: the verified papers are scientific, not regulatory, documents. They do not report agency reviews, safety dossiers, ingredient concentration limits or marketing authorisations.

What the Studies Did Not Test

1. Human clinical outcomes. No verified study reported wrinkle depth, elasticity, hydration or investigator-rated appearance changes in human volunteers using Syn-Ake; the ingredient study was in silico and in vitro (PMID 37349941).
2. Comparison with injectable neuromodulators. No verified head-to-head study compared a topical peptide with any approved neuromodulator product.
3. Skin penetration. No verified study measured whether the ingredient reaches neuromuscular junctions in intact human skin, despite detailed receptor-interface mapping for waglerin-1 (PMID 11724791).
4. Dose-response. No verified study reported a concentration-response relationship for the ingredient in humans.
5. Repeat-exposure safety. No verified study reported irritation, sensitisation or cumulative-use outcomes.
6. Special populations. No verified study reported use in pregnancy, lactation, paediatric or immunocompromised populations.

Readers evaluating claims about this ingredient can hold them against a simple test: does the claim describe something a listed study actually measured, in the system it measured it in? Venom proteomics, receptor mutagenesis and computational modelling are each rigorous within their scope, and each stops well short of a human cosmetic outcome. This page is educational only and is not medical advice; questions about skin, medication or any product should be directed to a licensed physician.

References

• Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests (Journal of Biomolecular Structure & Dynamics, 2024)
• Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream (Journal of Molecular Evolution, 2017)
• Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors (Journal of Biological Chemistry, 2002)
• Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site (Biochemistry, 2002)
• Peptide-toxin tools for probing the expression and function of fetal and adult subtypes of the nicotinic acetylcholine receptor (Annals of the New York Academy of Sciences, 2008)
• Azemiopsin from Azemiops feae viper venom, a novel polypeptide ligand of nicotinic acetylcholine receptor (Journal of Biological Chemistry, 2012)
• Immobilization with atrophy induces de novo expression of neuronal nicotinic α7 acetylcholine receptors in muscle contributing to neurotransmission (Anesthesiology, 2014)
• Proteomic Characterization and Comparison of Malaysian Tropidolaemus wagleri and Cryptelytrops purpureomaculatus Venom Using Shotgun-Proteomics (Toxins, 2016)
• Venomics of Tropidolaemus wagleri, the sexually dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal (Scientific Reports, 2017)
• De Novo Assembly of Venom Gland Transcriptome of Tropidolaemus wagleri (Temple Pit Viper, Malaysia) and Insights into the Origin of Its Major Toxin, Waglerin (Toxins, 2023)
• From genome to "venome": molecular origin and evolution of the snake venom proteome inferred from phylogenetic analysis of toxin sequences and related body proteins (Genome Research, 2005)
• Binding of Ni2+ and Cu2+ ions to peptides with a Cys-His motif (Dalton Transactions, 2008)